Prelude Therapeutics (PRLD) Liabilities and Shareholders Equity (2019 - 2026)

Prelude Therapeutics (PRLD) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $119.6 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 15.3% year-over-year to $119.6 million; the trailing twelve-month figure through Mar 2026 stood at $470.6 million (down 36.25% YoY), and the FY2025 full-year result was $141.3 million, down 19.49% from the prior year.
• Liabilities and Shareholders Equity eased to $119.6 million in Q1 2026, from $141.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $280.7 million in Q1 2022 to a low of $94.8 million in Q3 2025.
• A 5-year average of $204.3 million and a median of $220.5 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity advanced 25.93% in 2023 and tumbled 51.95% in 2025, its largest moves.
• Tracing PRLD's Liabilities and Shareholders Equity over 5 years: stood at $220.5 million in 2022, then rose by 25.93% to $277.7 million in 2023, then tumbled by 36.79% to $175.5 million in 2024, then slipped by 19.49% to $141.3 million in 2025, then dropped by 15.34% to $119.6 million in 2026.
• Business Quant data shows PRLD's Liabilities and Shareholders Equity at $119.6 million in Q1 2026, $141.3 million in Q4 2025, and $94.8 million in Q3 2025.